NCT02142296View on ClinicalTrials.gov

Eylea to Treat Retinal Pigment Epithelial Detachment (RPED) Secondary to Wet Age-Related Macular Degeneration (wAMD)

PHASE4CompletedINTERVENTIONAL
Enrollment

37

Participants

Timeline

Start Date

May 31, 2014

Primary Completion Date

November 30, 2016

Study Completion Date

November 30, 2016

Conditions
Retinal Pigment Epithelial Detachment Secondary to Age-related Macular Degeneration
Interventions
DRUG

Eylea

monthly injections for 3 months and then every other month to 1 year. volume administered is 0.05ml

Trial Locations (1)

N6A 4V2

Ivey Eye Institute, London

All Listed Sponsors
lead

London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's

OTHER

NCT02142296 - Eylea to Treat Retinal Pigment Epithelial Detachment (RPED) Secondary to Wet Age-Related Macular Degeneration (wAMD) | Biotech Hunter | Biotech Hunter